Theralase Technologies Inc.

0.2572-0.0075-2.83%Vol 55.90K1Y Perf 67.99%
Dec 8th, 2021 13:17
BID0.0000 ASK0.0000
Open0.2695 Previous Close0.2647
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.44
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
74.82 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha0.00 Standard Deviation0.21
Beta1.64 

Today's Price Range

0.25490.2735

52W Range

0.13330.2989

5 Year PE Ratio Range

-6.7000-7.7000

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
27.57%
1 Month
65.85%
3 Months
42.70%
6 Months
36.09%
1 Year
67.99%
3 Years
8.31%
5 Years
23.46%
10 Years
0.00%

TickerPriceChg.Chg.%
TLTFF0.2572-0.0075-2.83
AAPL174.303.12001.82
GOOG2 959.75-0.9800-0.03
MSFT332.50-2.4200-0.72
XOM62.460.19000.31
WFC49.43-0.8200-1.63
JNJ163.910.55000.34
FB330.737.92002.45
GE98.470.92000.94
JPM160.63-1.9400-1.19
Financial StrengthValueIndustryS&P 500US Markets
7.10
8.40
0.00
0.01
-580.60
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
38.10
-411.50
-385.50
-416.40
-
RevenueValueIndustryS&P 500US Markets
651.66K
0.00
-16.09
-17.79
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume55.90K
Shares Outstanding0
Shares Float204.28M
Trades Count13
Dollar Volume14.69K
Avg. Volume152.64K
Avg. Weekly Volume522.78K
Avg. Monthly Volume256.83K
Avg. Quarterly Volume133.02K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Theralase Technologies Inc.

Theralase Technologies Inc is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Founded in 1994, the company's operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states.

CEO: Arkady Mandel

Telephone: +1 416 699-5273

Address: 41 Hollinger Road, Toronto M4B 3G4, ON, CAN

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

News